By 2016, radical prostatectomy use nearly equaled radiation therapy use for high-risk prostate cancer.
The latest analyses found 5-year overall survival benefits across low-, intermediate-, and high-risk subgroups of men with chemotherapy-naïve metastatic castration-resistant prostate cancer.
The model, based on routinely collected clinical characteristics, provides information that can enhance discussions between health care professionals and patients on active surveillance intensity.
A study showed that mortality risk was reduced by 59% for patients who underwent complete metastasectomy compared with those who did not.
The authors of a new review discuss priorities, adjustments, and tailored approaches to prostate cancer management during the COVID-19 pandemic.
The new stratification model may aid treatment decision-making for men with “favorable,” high-risk, or “very” high-risk prostate cancer.
Radiation therapy for higher-risk prostate cancer can be delayed for up to 6 months following initiation of hormonal therapy without incurring a greater mortality risk, a finding that has implications for patient care during the COVID-19 pandemic.
In a study, modified Glasgow prognostic score predicted nonorgan-confined disease and lymph node invasion at surgery.
In a large case series, stage IV disease at diagnosis and 3 or more metastatic sites were both associated with worse prognosis.